Literature DB >> 32330387

Removal of Fc Glycans from [89Zr]Zr-DFO-Anti-CD8 Prevents Peripheral Depletion of CD8+ T Cells.

Jordan M White1, Outi M Keinänen2,3, Brendon E Cook2,4, Brian M Zeglis2,4,3, Heather M Gibson1, Nerissa T Viola1.   

Abstract

The N-linked biantennary glycans on the heavy chain of immunoglobulin G (IgG) antibodies (mAbs) are instrumental in the recognition of the Fc region by Fc-gamma receptors (FcγR). In the case of full-length mAb-based imaging tracers targeting immune cell populations, these Fc:FcγR interactions can potentially deplete effector cells responsible for tumor clearance. To bypass this problem, we hypothesize that the enzymatic removal of the Fc glycans will disrupt Fc:FcγR interactions and spare tracer-targeted immune cells from depletion during immunopositron emission tomography (immunoPET) imaging. Herein, we compared the in vitro and in vivo properties of 89Zr-radiolabeled CD8-specific murine mAb (anti-CD8wt, clone 2.43), a well-known depleting mAb, and its deglycosylated counterpart (anti-CD8degly). Deglycosylation was achieved via enzymatic treatment with the peptide: N-glycosidase F (PNGaseF). Both anti-CD8wt and anti-CD8degly mAbs were conjugated to p-SCN-Bn-desferrioxamine (DFO) and labeled with 89Zr. Bindings of both DFO-conjugated mAbs to FcγR and CD8+ splenocytes were compared. In vivo imaging and distribution studies were conducted to examine the specificity and pharmacokinetics of the radioimmunoconjugates in tumor-naive and CT26 colorectal tumor-bearing mice. Ex vivo analysis of CD8+ T cell population in spleens and tumors obtained postimaging were measured via flow cytometry and qRT-PCR. The removal of the Fc glycans from anti-CD8wt was confirmed via SDS-PAGE. A reduction in FcγR interaction was exhibited by DFO-anti-CD8degly, while its binding to CD8 remained unchanged. Tissue distribution showed similar pharmacokinetics of [89Zr]Zr-DFO-anti-CD8degly and the wt radioimmunoconjugate. In vivo blocking studies further demonstrated retained specificity of the deglycosylated radiotracer for CD8. From the imaging studies, no difference in accumulation in both spleens and tumors was observed between both radiotracers. Results from the flow cytometry analysis confirmed depletion of CD8+ T cells in spleens of mice administered with DFO-anti-CD8wt, whereas an increase in CD8+ T cells was shown with DFO-anti-CD8degly. No statistically significant difference in tumor infiltrating CD8+ T cells was observed in cohorts administered with the probes when compared to control unmodulated mice. CD8 mRNA levels from excised tumors showed increased transcripts of the antigen in mice administered with [89Zr]Zr-DFO-anti-CD8degly compared to mice imaged with [89Zr]Zr-DFO-anti-CD8wt. In conclusion, the removal of Fc glycans offers a straightforward approach to develop full length antibody-based imaging probes specifically for detecting CD8+ immune molecules with no consequential depletion of their target cell population in peripheral tissues.

Entities:  

Keywords:  CD8 imaging; Fc glycan removal; immune cell depletion; immunoPET

Mesh:

Substances:

Year:  2020        PMID: 32330387      PMCID: PMC7307332          DOI: 10.1021/acs.molpharmaceut.0c00270

Source DB:  PubMed          Journal:  Mol Pharm        ISSN: 1543-8384            Impact factor:   4.939


  38 in total

1.  IFNγ PET Imaging as a Predictive Tool for Monitoring Response to Tumor Immunotherapy.

Authors:  Heather M Gibson; Brooke N McKnight; Agnes Malysa; Greg Dyson; Wendy N Wiesend; Claire E McCarthy; Joyce Reyes; Wei-Zen Wei; Nerissa T Viola-Villegas
Journal:  Cancer Res       Date:  2018-08-16       Impact factor: 12.701

2.  The Impact of FcγRI Binding on Immuno-PET.

Authors:  Delphine Vivier; Sai Kiran Sharma; Pierre Adumeau; Cindy Rodriguez; Kimberly Fung; Brian M Zeglis
Journal:  J Nucl Med       Date:  2019-02-07       Impact factor: 10.057

Review 3.  Advances in PET Detection of the Antitumor T Cell Response.

Authors:  M N McCracken; R Tavaré; O N Witte; A M Wu
Journal:  Adv Immunol       Date:  2016-04-05       Impact factor: 3.543

4.  Optimization of Enzymatic Antibody Fragmentation for Yield, Efficiency, and Binding Affinity.

Authors:  Andrew W L Kinman; Rebecca R Pompano
Journal:  Bioconjug Chem       Date:  2019-01-28       Impact factor: 4.774

Review 5.  How to differentiate pseudoprogression from true progression in cancer patients treated with immunotherapy.

Authors:  Yiming Ma; Qiwei Wang; Qian Dong; Lei Zhan; Jingdong Zhang
Journal:  Am J Cancer Res       Date:  2019-08-01       Impact factor: 6.166

6.  First-in-Humans Imaging with 89Zr-Df-IAB22M2C Anti-CD8 Minibody in Patients with Solid Malignancies: Preliminary Pharmacokinetics, Biodistribution, and Lesion Targeting.

Authors:  Neeta Pandit-Taskar; Michael A Postow; Matthew D Hellmann; James J Harding; Christopher A Barker; Joseph A O'Donoghue; Martha Ziolkowska; Shutian Ruan; Serge K Lyashchenko; Frank Tsai; Michael Farwell; Tara C Mitchell; Ron Korn; William Le; Jason S Lewis; Wolfgang A Weber; Deepak Behera; Ian Wilson; Michael Gordon; Anna M Wu; Jedd D Wolchok
Journal:  J Nucl Med       Date:  2019-10-04       Impact factor: 10.057

7.  Predicting the response to CTLA-4 blockade by longitudinal noninvasive monitoring of CD8 T cells.

Authors:  Mohammad Rashidian; Jessica R Ingram; Michael Dougan; Anushka Dongre; Katherine A Whang; Camille LeGall; Juan J Cragnolini; Brian Bierie; Monica Gostissa; James Gorman; Gijsbert M Grotenbreg; Atul Bhan; Robert A Weinberg; Hidde L Ploegh
Journal:  J Exp Med       Date:  2017-06-30       Impact factor: 14.307

Review 8.  Emerging Role of the Spleen in the Pharmacokinetics of Monoclonal Antibodies, Nanoparticles and Exosomes.

Authors:  Mauro Cataldi; Chiara Vigliotti; Teresa Mosca; MariaRosaria Cammarota; Domenico Capone
Journal:  Int J Mol Sci       Date:  2017-06-10       Impact factor: 5.923

Review 9.  Recent Advances in Zirconium-89 Chelator Development.

Authors:  Nikunj B Bhatt; Darpan N Pandya; Thaddeus J Wadas
Journal:  Molecules       Date:  2018-03-12       Impact factor: 4.411

10.  The Influence of Glycans-Specific Bioconjugation on the FcγRI Binding and In vivo Performance of 89Zr-DFO-Pertuzumab.

Authors:  Delphine Vivier; Kimberly Fung; Cindy Rodriguez; Pierre Adumeau; Gary A Ulaner; Jason S Lewis; Sai Kiran Sharma; Brian M Zeglis
Journal:  Theranostics       Date:  2020-01-01       Impact factor: 11.556

View more
  2 in total

1.  Development and comparison of three 89Zr-labeled anti-CLDN18.2 antibodies to noninvasively evaluate CLDN18.2 expression in gastric cancer: a preclinical study.

Authors:  Guilan Hu; Wenjia Zhu; Yu Liu; Yuan Wang; Zheng Zhang; Shikun Zhu; Wenwen Duan; Peipei Zhou; Chao Fu; Fang Li; Li Huo
Journal:  Eur J Nucl Med Mol Imaging       Date:  2022-03-26       Impact factor: 10.057

2.  Homogeneity of antibody-drug conjugates critically impacts the therapeutic efficacy in brain tumors.

Authors:  Yasuaki Anami; Yoshihiro Otani; Wei Xiong; Summer Y Y Ha; Aiko Yamaguchi; Kimberly A Rivera-Caraballo; Ningyan Zhang; Zhiqiang An; Balveen Kaur; Kyoji Tsuchikama
Journal:  Cell Rep       Date:  2022-05-24       Impact factor: 9.995

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.